Cell Therapy & Colorectal Cancer Survival: New Study
- Colorectal cancer (CRC) patients may see improved outcomes with cytokine-induced killer (CIK) cell therapy, according to a new study.
- Yi Zhang, director of the Biotherapy Centre at the First Affiliated Hospital of Zhengzhou University, noted that while stages II-III CRC patients frequently enough face high recurrence and...
- The study also identified a potential biomarker to predict treatment response. By analyzing blood samples, researchers discovered that carcinoembryonic antigen (CEA) levels could indicate whether a patient would...
Colorectal cancer patients may experience improved survival rates thanks to innovative CIK cell therapy,according to a groundbreaking new study. Researchers found that combining CIK cell therapy with conventional treatments substantially boosts outcomes for those battling this disease. The study also reveals that carcinoembryonic antigen (CEA) levels could serve as a critical biomarker-a potential early indicator of a patientS response to the CIK treatment. This discovery could transform how colorectal cancer, sometimes called colon cancer, is treated. News Directory 3 highlights this promising research. The findings, based on a decade-long patient follow-up, have the potential to reshape clinical practices. Discover what’s next as scientists explore combining CIK therapy with other treatments!
cell Therapy Boosts Survival in Colorectal Cancer Patients, Study Finds
Colorectal cancer (CRC) patients may see improved outcomes with cytokine-induced killer (CIK) cell therapy, according to a new study. Researchers found that CIK cell therapy, used in conjunction with surgery or chemotherapy, significantly enhanced survival rates.
Dr. Yi Zhang, director of the Biotherapy Centre at the First Affiliated Hospital of Zhengzhou University, noted that while stages II-III CRC patients frequently enough face high recurrence and metastasis risks after surgery, CIK cell therapy offers a promising avenue for improved survival.
The study also identified a potential biomarker to predict treatment response. By analyzing blood samples, researchers discovered that carcinoembryonic antigen (CEA) levels could indicate whether a patient would benefit from CIK cell therapy. Elevated CEA levels after surgery are typically associated with poor prognosis and recurrence.
According to Zhang, this finding could lead to a simple pre-treatment blood test, possibly improving patient survival by identifying suitable candidates for CIK cell therapy. “The long-term effects of CIK cell therapy for CRC patients had not been understood until now,” Zhang said. “The promising results of our study will hopefully facilitate the widespread adoption of cell therapies for treating malignant tumors including CRC.”
The retrospective study tracked two patient groups from 2008 to 2014, with follow-ups through January 2020. One group received CIK cell therapy alongside chemotherapy or surgery, while the control group underwent chemotherapy and/or surgery alone.
Researchers monitored progression-free survival and overall survival, investigating biomarkers in patient blood to predict survival rates. Future research will explore combining CIK therapy with chemotherapy, radiotherapy, and immunotherapy, and also prospective clinical studies to solidify CIK cell therapy as a standard CRC treatment.